San Diego-based Trius Therapeutics hopes to sell 6 million shares to investors at a range of $12 to $14 apiece, according to an updated IPO prospectus filed with the Securities & Exchange Commission. The company, a developer of new antibiotics, is scheduled to attempt its IPO the week of March 15, according to a calendar from Renaissance Capital. If the deal is completed, Trius plans to trade under the ticker “TSRX.” The major stockholders who stand to gain are Sofinnova Ventures, InterWest Partners, Versant Ventures, Prism Venture Partners, and Kleiner Perkins Caufield & Byers.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
